| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
79,240,000 |
| Market
Cap: |
110.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.9043 - $6.58 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Alector is a clinical stage biopharmaceutical company developing immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. Co.'s product candidate, AL001, modulates progranulin (PRGN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. AL101, Co.'s second product candidate in its PGRN portfolio, is designed to treat people suffering from more prevalent neurodegenerative diseases. AL003 is Co.'s second therapeutic candidate designed to treat patients with Alzheimer's disease. AL044 is Co.'s therapeutic candidate for neurodegeneration.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
93,465 |
197,265 |
423,268 |
1,578,997 |
| Total Sell Value |
$125,195 |
$277,507 |
$1,136,023 |
$8,011,014 |
| Total People Sold |
4 |
5 |
7 |
9 |
| Total Sell Transactions |
4 |
8 |
19 |
37 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wong-Sarad Grace |
Principal Accounting Officer |
• – – |
2025-06-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
109,358 |
|
- |
|
| Berkley Neil Lindsay |
Principal Financial Officer |
• – – |
2025-06-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
362,412 |
|
- |
|
| Yaffe Kristine |
|
– • – |
2025-06-20 |
4 |
S |
$1.44 |
$1,440 |
D/D |
(1,000) |
95,409 |
|
-1% |
|
| Hammond Paula |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
28,700 |
88,909 |
|
- |
|
| Lavigne Louis J Jr |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
28,700 |
99,409 |
|
- |
|
| Desouza Errol B |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
28,700 |
69,950 |
|
- |
|
| Garofalo Elizabeth A. |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
28,700 |
89,950 |
|
- |
|
| Scheller Richard H |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
28,700 |
95,366 |
|
- |
|
| Altmeyer Mark |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
28,700 |
69,950 |
|
- |
|
| Yaffe Kristine |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
28,700 |
96,409 |
|
- |
|
| Grasso Marc |
Chief Financial Officer |
• – – |
2025-06-02 |
4 |
S |
$1.34 |
$22,068 |
D/D |
(16,488) |
296,072 |
|
-7% |
|
| Rosenthal Arnon |
Chief Executive Officer |
• • – |
2025-06-02 |
4 |
S |
$1.34 |
$69,713 |
D/D |
(52,087) |
2,414,657 |
|
-7% |
|
| Kenkare-Mitra Sara |
President and Head of R&D |
• – – |
2025-06-02 |
4 |
S |
$1.34 |
$31,974 |
D/D |
(23,890) |
512,252 |
|
-7% |
|
| Scheller Richard H |
|
– • – |
2025-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
15,833 |
66,666 |
|
- |
|
| Rosenthal Arnon |
Chief Executive Officer |
• • – |
2025-03-03 |
4 |
S |
$1.47 |
$59,176 |
D/D |
(40,330) |
2,466,744 |
|
-5% |
|
| Kenkare-Mitra Sara |
President and Head of R&D |
• – – |
2025-03-03 |
4 |
S |
$1.47 |
$42,662 |
D/D |
(29,073) |
536,142 |
|
-5% |
|
| Grasso Marc |
Chief Financial Officer |
• – – |
2025-03-03 |
4 |
S |
$1.47 |
$26,547 |
D/D |
(18,091) |
312,560 |
|
-5% |
|
| Romano Gary |
Chief Medical Officer |
• – – |
2025-03-03 |
4 |
S |
$1.47 |
$23,927 |
D/D |
(16,306) |
332,977 |
|
-5% |
|
| Rosenthal Arnon |
Chief Executive Officer |
• • – |
2024-12-02 |
4 |
S |
$2.52 |
$131,442 |
D/D |
(52,172) |
2,507,074 |
|
61% |
|
| Grasso Marc |
Chief Financial Officer |
• – – |
2024-12-02 |
4 |
S |
$2.52 |
$41,542 |
D/D |
(16,489) |
330,651 |
|
61% |
|
| Romano Gary |
Chief Medical Officer |
• – – |
2024-12-02 |
4 |
S |
$2.52 |
$37,519 |
D/D |
(14,892) |
349,283 |
|
61% |
|
| Kenkare-Mitra Sara |
President and Head of R&D |
• – – |
2024-12-02 |
4 |
S |
$2.52 |
$66,764 |
D/D |
(26,500) |
565,215 |
|
61% |
|
| Kenkare-Mitra Sara |
President and Head of R&D |
• – – |
2024-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
591,715 |
|
- |
|
| Rosenthal Arnon |
Chief Executive Officer |
• • – |
2024-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
610,500 |
2,559,246 |
|
- |
|
| Romano Gary |
Chief Medical Officer |
• – – |
2024-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
184,380 |
364,175 |
|
- |
|
290 Records found
|
|
Page 1 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.08 (5.41%) 
